AzTrials
AzTrials

Active Psoriatic ArthritisPhase 2NCT02980692

Efficacy and Safety Study of SUNPG1623

A Phase 2 study testing SUNPG1623 I, SUNPG1623 II and SUNPG1623 III in people with Active Psoriatic Arthritis, run by Sun Pharmaceutical Industries Limited at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623 Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Active Psoriatic Arthritis
What is being tested?
SUNPG1623 I, SUNPG1623 II and SUNPG1623 III
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
391 participants
Where
1 siteUnited States
Study dates
19 Apr 2017to 24 Sep 2019
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject has provided written informed consent
  • Subject is ≥ 18 years of age at time of Screening
  • Subject must be on stable dose of NSAID for ≥ 4 weeks prior to initiation of IMP
  • Subject has a negative evaluation for TB within 4 weeks before initiating IMP
  • Subject has a diagnosis of PsA (by the Classification of Psoriatic Arthritis [CASPAR] criteria) with symptoms present for at least 6 months.
  • Subject has ≥ 3 tender and ≥ 3 swollen joints at Screening and Baseline.

Who cannot join

  • Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition
  • Subject has an active infection or history of infections
  • Subject has any concurrent medical condition or uncontrolled, clinically significant systemic disease
  • Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus

Trial locations and contacts

1 site in 1 country.

United States1 site
  • SPARC Site 1

    Middleburg Heights, Ohio, 44130

Other trials in United States

About this study

Official title: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis

This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623

Being tested
SUNPG1623 I, SUNPG1623 II, SUNPG1623 III, SUNPG1623 IV, PLACEBO

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SUNPG1623 IDrug

    injection

  • SUNPG1623 IIDrug

    injection

  • SUNPG1623 IIIDrug

    injection

  • SUNPG1623 IVDrug

    injection

  • PLACEBODrug

    injection

Study groups in NCT02980692
Study groupRoleWhat they receive
SUNPG1623 dose IExperimentallow range dose
Receives: Drug: SUNPG1623 I
SUNPG1623 dose IIExperimentalmid range dose
Receives: Drug: SUNPG1623 II; Drug: PLACEBO
SUNPG1623 dose IIIExperimentalmid range dose
Receives: Drug: SUNPG1623 III; Drug: PLACEBO
SUNPG1623 dose IVExperimentalmid range dose to high dose
Receives: Drug: SUNPG1623 IV; Drug: PLACEBO
PlaceboPlacebo comparatormid range dose to high dose
Receives: Drug: PLACEBO

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate

    The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.

    For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

    Measured: week 24

Secondary outcomes (26)
  1. Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate

    The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.

    For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

    Measured: week 52

  2. Proportion of Subjects Achieving American College of Rheumatology50 Response Rate

    The American College of Rheumatology50 response measured the percentage of subjects with at least a 50% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.

    For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52

  3. Proportion of Subjects Achieving American College of Rheumatology70 Response Rate

    The American College of Rheumatology70 response measured the percentage of subjects with at least a 50% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.

    For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, week 24, and week 52

  4. Change From Baseline in Tender Joint Counts

    Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

  5. Change From Baseline in Tender Joint Counts

    Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

    Measured: Week 52

  6. Change From Baseline in Swollen Joint Counts

    Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

  7. Change From Baseline in Swollen Joint Counts

    Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

    Measured: Week 52

  8. Physician Global Assessment of Disease Activity Visual Analog Scale

    100 mm Visual analog scale with descriptors (verbal) : "very good" (0) to "very poor" (100)

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

  9. Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale

    100 mm Visual analog scale with descriptors (verbal) : "very good" (0) to "very poor" (100)

    Measured: Week 52

  10. Patient's Global Assessment of Disease Activity

    100 mm Visual analog scale descriptors (verbal) : "very well" (0) to "very poorly"(100)

    Measured: week 1, week 4, week 8, week 12, week 16, week 20 and week 24

  11. Change From Baseline in Patient's Global Assessment of Disease Activity

    100 mm Visual analog scale descriptors (verbal) : "very well" (0) to "very poorly"(100)

    Measured: Week 52

  12. Patient's Pain Assessment

    100 mm Visual Analog Scale with scale (verbal descriptors) "no pain" (0) to "worst possible pain" (100).

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

  13. Change From Baseline in Patient's Pain Assessment

    100 mm Visual Analog Scale with scale (verbal descriptors) "no pain" (0) to "worst possible pain" (100).

    Measured: Week 52

  14. Health Assessment Questionnaire- Disability Index

    eight categories assessed by the Health Assessment Questionnaire - Disability Index 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip and 8) common daily activities was scored as 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) or 3 (unable to do).

    The score for the disability index is the mean of the 8 category scores. If more than 2 of the categories, or 25%, are missing, the scale is not scored. If fewer than 2 of the categories are missing, the sum of the categories is divided by the number of answered categories. A higher score indicates greater disability

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

  15. Change From Baseline in Health Assessment Questionnaire- Disability Index

    eight categories assessed by the Health Assessment Questionnaire - Disability Index 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip and 8) common daily activities was scored as 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) or 3 (unable to do).

    The score for the disability index is the mean of the 8 category scores. If more than 2 of the categories, or 25%, are missing, the scale is not scored. If fewer than 2 of the categories are missing, the sum of the categories is divided by the number of answered categories. A higher score indicates greater disability

    Measured: Week 52

  16. Acute Phase C - Reactive Protein

    C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood.

    CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

  17. Acute Phase C - Reactive Protein

    C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood.

    CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation.

    Change from Baseline in C-Reactive Protein.

    Measured: Week 52

  18. Erythrocyte Sedimentation Rate

    An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. This test help determine if you have a condition that causes inflammation.

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

  19. Change From Baseline in Erythrocyte Sedimentation Rate

    An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. This test help determine if you have a condition that causes inflammation.

    Measured: Week 52

  20. The Proportion of Subjects Who Require Adjustment of Background Therapy

    Measured: Week 16

  21. Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate

    The Disease Activity Score 28-item C-Reactive Protein: assessed across 28 joints including the shoulder, elbow, wrist, MCP (1 through 5), PIP (1 through 5) and knee, with all 14 joints assessed for each side of the body. It is a composite score derived from examination of the 28 joints for swelling and tenderness, global assessment of pain and overall status using a VAS and a blood marker of inflammation (hsCRP).

    DAS28-CRP(4) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 0.96 TJC- tender joint count, SJC- swollen joint count, CRP- C reactive protein, GH - patient global health

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and Week 52

  22. Minimal Disease Activity

    A psoriatic arthritis patient is defined as having a Minimal Disease Activity (MDA) response (Yes/No) when the patient meets at least 5 of the 7 following criteria:

    1. tender joint count ≤1;
    2. swollen joint count ≤1;
    3. PASI score ≤1 or BSA ≤3%;
    4. patient Arthritis Pain (VAS) ≤15 mm;
    5. patient's global arthritis assessment (VAS) ≤20 mm;
    6. HAQ-DI score ≤0.5;
    7. tender entheseal points (using LEI) ≤1.

    Measured: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52

  23. Change From Baseline in Leeds Dactylitis Index (LDI)

    tenderness score (0 = no tenderness, 1 = tender, 2 = tender and wince, and 3 = tender and withdraw)

    Total score= {[Circumference involved digit/ Circumference contralateral Digit (or Tables)] - 1x 100}x Tenderness score

    Standard reference: Hands Digit Men Women Thumb 70 58 Index 63 54 Middle 63 54 Ring 59 50 Little 52 44 Standard reference: Feet Digit Men Women Great Toe 82 72 Second 52 46 Middle 50 44 Fourth 50 44 Little 52 45

    The difference between circumference of affected finger and contralateral not affected digit cannot be defined for maximum value. Therefore, it is difficult to provide scale range for the final score. No theoretical range exists for the Leeds Dactylitis Index.

    Lower Leeds Dactylitis Index score represent better outcome.

    Measured: week 4, week 12, and week 24

  24. Change From Baseline in Leeds Dactylitis Index (LDI)

    tenderness score (0 = no tenderness, 1 = tender, 2 = tender and wince, and 3 = tender and withdraw)

    Total score= {[Circumference involved digit/ Circumference contralateral Digit (or Tables)] - 1x 100}x Tenderness score

    Standard reference: Hands Digit Men Women Thumb 70 58 Index 63 54 Middle 63 54 Ring 59 50 Little 52 44 Standard reference: Feet Digit Men Women Great Toe 82 72 Second 52 46 Middle 50 44 Fourth 50 44 Little 52 45

    The difference between circumference of affected finger and contralateral not affected digit cannot be defined for maximum value. Therefore, it is difficult to provide scale range for the final score. No theoretical range exists for the Leeds Dactylitis Index.

    Lower Leeds Dactylitis Index score represent better outcome.

    Measured: Week 52

  25. Change From Baseline in Leeds Enthesitis Index (LEI)

    The LEI examines tenderness at 6 sites:

    2 sites (left and right) at each of the lateral epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. For each entheseal site, assessment is made of the adjacent joint in terms of tenderness and soft-tissue swelling, with a score of 1 if present. The LEI score range is 0-6.

    Lower the score better is the outcome

    Measured: week 4, week 12 and week 24

  26. Change From Baseline in Leeds Enthesitis Index (LEI)

    The LEI examines tenderness at 6 sites:

    2 sites (left and right) at each of the lateral epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. For each entheseal site, assessment is made of the adjacent joint in terms of tenderness and soft-tissue swelling, with a score of 1 if present. The LEI score range is 0-6.

    Lower the score better is the outcome

    Measured: Week 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Dec 2016 (estimated)
  2. Study start19 Apr 2017
  3. Primary completion1 Mar 2019
  4. Study completion24 Sep 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
391 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02980692
Sponsor's protocol ID
CLR_16_23
Status last verified
Aug 2022
First submitted
30 Nov 2016
Last updated
27 Jan 2023
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, Chou RC, Mendelsohn AM, Rozzo SJ, Gottlieb A. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021 Sep;80(9):1147-1157. doi: 10.1136/annrheumdis-2020-219014. Epub 2021 May 13.

    PubMed 33985942

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing SUNPG1623 I, SUNPG1623 II and SUNPG1623 III in people with Active Psoriatic Arthritis, run by Sun Pharmaceutical Industries Limited at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 May 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate (time frame: week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02980692, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in